Raras
Buscar doenças, sintomas, genes...
Distrofia muscular progressiva
ORPHA:206644DOENÇA RARA

Distrofia miotónica (português europeu) ou distrofia miotônica (português brasileiro) é uma doença genética crónica que afeta a função muscular. Os sintomas mais evidentes são fraqueza e atrofia muscular progressivas. Em muitos casos os músculos contraem-se e são incapazes de relaxar. Entre outros possíveis sintomas estão cataratas, deficiência intelectual e problemas na condução elétrica do coração. Em homens, pode ocorrer calvície precoce e infertilidade.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença rara caracterizada por fraqueza muscular progressiva, podendo apresentar bolhas intraepidérmicas, atrofia da língua e obstrução das vias aéreas. Afeta também o coração com fibrose e extrassístoles ventriculares, além de neuropatia periférica e contraturas.

Pesquisas ativas
30 ensaios
856 total registrados no ClinicalTrials.gov
Publicações científicas
1.620 artigos
Último publicado: 2026 Apr 9
Medicamentos
4 registrados
MEXILETINE, DEFLAZACORT, TIDEGLUSIB

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
MEXILETINEDEFLAZACORTTIDEGLUSIBSTAMULUMAB
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
146 sintomas
🧠
Neurológico
47 sintomas
🦴
Ossos e articulações
44 sintomas
❤️
Coração
40 sintomas
👁️
Olhos
31 sintomas
📏
Crescimento
23 sintomas

+ 239 sintomas em outras categorias

Características mais comuns

Fraqueza muscular
Bolhas intraepidérmicas
Atrofia da língua
Obstrução das vias aéreas
Pernas inquietas
Contratura do cotovelo
657sintomas
Sem dados (657)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 657 características clínicas mais associadas, ordenadas por frequência.

Fraqueza muscularMuscle weakness
Bolhas intraepidérmicasIntra-epidermal blistering
Atrofia da línguaTongue atrophy
Obstrução das vias aéreasAirway obstruction
Pernas inquietasRestless legs

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.620PubMed
Últimos 10 anos73publicações
Pico202511 papers
Linha do tempo
2026Hoje · 2026🧪 1978Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

57 genes identificados com associação a esta condição.

CRPPAD-ribitol-5-phosphate cytidylyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:22522421, PubMed:26687144, PubMed:26923585, PubMed:27130732, PubMed:27601598). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:26687144, PubMed:26923585, PubMed:27130732). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carboh

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Umuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:37276UniProt:A4D126
TNPO3Transportin-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Importin, which transports target proteins into the nucleus (PubMed:10366588, PubMed:10713112, PubMed:11517331, PubMed:12628928, PubMed:24449914). Specifically mediates the nuclear import of splicing factor serine/arginine (SR) proteins, such as RBM4, SFRS1 and SFRS2, by recognizing phosphorylated SR domains (PubMed:10366588, PubMed:10713112, PubMed:11517331, PubMed:12628928, PubMed:24449914). Also mediates the nuclear import of serine/arginine (SR) protein CPSF6, independently of CPSF6 phosphor

LOCALIZAÇÃO

Nucleus envelopeCytoplasm

MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal dominant 2

An autosomal dominant myopathy characterized by proximal muscle weakness primarily affecting the lower limbs, but also affecting the upper limbs in most patients. Affected individuals also have distal muscle weakness of the hands and lower leg muscles. The disease has generally a benign clinical course but some individuals with childhood or juvenile onset manifest severe widespread myopathy, leading to wheelchair dependency and respiratory insufficiency. Muscle biopsy shows dystrophic changes with abnormal nuclei, rimmed vacuoles, and filamentous inclusions.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
79.5 TPM
Fibroblastos
47.6 TPM
Testículo
40.2 TPM
Cérebro - Hemisfério cerebelar
35.1 TPM
Ovário
32.1 TPM
OUTRAS DOENÇAS (2)
autosomal dominant limb-girdle muscular dystrophy type 1Fprimary biliary cholangitis
HGNC:17103UniProt:Q9Y5L0
FKTNRibitol-5-phosphate transferase FKTNDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842). This constitutes the first step in the formation of the ribitol 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligan

LOCALIZAÇÃO

Golgi apparatus membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.9 TPM
Nervo tibial
12.9 TPM
Ovário
12.1 TPM
Útero
10.6 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4autosomal recessive limb-girdle muscular dystrophy type 2Mmuscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4dilated cardiomyopathy 1X
HGNC:3622UniProt:O75072
POMT2Protein O-mannosyl-transferase 2Candidate gene tested inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
59.9 TPM
Pituitária
28.9 TPM
Tireoide
27.7 TPM
Cervix Endocervix
21.2 TPM
Cerebelo
21.2 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2autosomal recessive limb-girdle muscular dystrophy type 2Nmuscle-eye-brain disease
HGNC:19743UniProt:Q9UKY4
POMGNT1Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3,

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
DAG1 core M1 glycosylationsDAG1 core M2 glycosylationsMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3

An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
61.9 TPM
Tireoide
61.2 TPM
Brain Spinal cord cervical c-1
57.1 TPM
Testículo
54.0 TPM
Nervo tibial
52.7 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3retinitis pigmentosa 76autosomal recessive limb-girdle muscular dystrophy type 2O
HGNC:19139UniProt:Q8WZA1
JAG2Protein jagged-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Putative Notch ligand involved in the mediation of Notch signaling. Involved in limb development (By similarity)

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (7)
Activated NOTCH1 Transmits Signal to the NucleusConstitutive Signaling by NOTCH1 PEST Domain MutantsNOTCH2 Activation and Transmission of Signal to the NucleusNOTCH3 Activation and Transmission of Signal to the NucleusConstitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 27

An autosomal recessive muscular disorder characterized by progressive muscle weakness most prominent in the proximal lower limb and axial muscles, and resulting in walking difficulty or loss of ambulation. Additional more variable features include neck muscle weakness, scoliosis, and joint contractures. Some affected individuals manifest impaired intellectual development or speech delay, cardiomyopathy, and cardiac arrhythmia. Muscle biopsy shows non-specific dystrophic changes.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
56.8 TPM
Skin Not Sun Exposed Suprapubic
51.0 TPM
Skin Sun Exposed Lower leg
44.8 TPM
Mama
31.5 TPM
Próstata
31.1 TPM
OUTRAS DOENÇAS (1)
muscular dystrophy, limb-girdle, autosomal recessive 27
HGNC:HGNC:6189UniProt:Q9Y219
SGCBBeta-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 4

An autosomal recessive degenerative myopathy characterized by pelvic and shoulder muscle wasting, onset usually in childhood and variable progression rate.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
100.8 TPM
Aorta
89.2 TPM
Artéria tibial
80.8 TPM
Artéria coronária
72.2 TPM
Fibroblastos
69.7 TPM
OUTRAS DOENÇAS (2)
autosomal recessive limb-girdle muscular dystrophy type 2Eautosomal recessive limb-girdle muscular dystrophy
HGNC:10806UniProt:Q16585
LRP12Low-density lipoprotein receptor-related protein 12Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Probable receptor, which may be involved in the internalization of lipophilic molecules and/or signal transduction. May act as a tumor suppressor

LOCALIZAÇÃO

MembraneMembrane, coated pit

VIAS BIOLÓGICAS (1)
Retinoid metabolism and transport
MECANISMO DE DOENÇA

Oculopharyngodistal myopathy 1

A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM1 inheritance pattern is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.3 TPM
Útero
17.0 TPM
Artéria tibial
10.5 TPM
Fallopian Tube
10.3 TPM
Aorta
9.5 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (3)
oculopharyngodistal myopathy 1amyotrophic lateral sclerosis 28oculopharyngodistal myopathy
HGNC:31708UniProt:Q9Y561
MYH7Myosin-7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle

LOCALIZAÇÃO

Cytoplasm, myofibrilCytoplasm, myofibril, sarcomere

MECANISMO DE DOENÇA

Cardiomyopathy, familial hypertrophic, 1

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
4513.7 TPM
Músculo esquelético
3692.8 TPM
Coração - Átrio
592.2 TPM
Pâncreas
5.3 TPM
Hipotálamo
4.9 TPM
OUTRAS DOENÇAS (12)
MYH7-related skeletal myopathymyopathy, myosin storage, autosomal recessivedilated cardiomyopathy 1Scongenital myopathy 7A, myosin storage, autosomal dominant
HGNC:7577UniProt:P12883
SYNE1Nesprin-1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and p

LOCALIZAÇÃO

Nucleus outer membraneNucleusNucleus envelopeCytoplasm, cytoskeletonCytoplasm, myofibril, sarcomereGolgi apparatus

VIAS BIOLÓGICAS (1)
Meiotic synapsis
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 8

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR8 is an autosomal recessive form.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
64.7 TPM
Cérebro - Hemisfério cerebelar
59.5 TPM
Ovário
38.9 TPM
Aorta
30.2 TPM
Tireoide
27.1 TPM
OUTRAS DOENÇAS (5)
Emery-Dreifuss muscular dystrophy 4, autosomal dominantautosomal recessive ataxia, Beauce typearthrogryposis multiplex congenita 3, myogenic typeautosomal recessive myogenic arthrogryposis multiplex congenita
HGNC:17089UniProt:Q8NF91
MYOTMyotilinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of a complex of multiple actin cross-linking proteins. Involved in the control of myofibril assembly and stability at the Z lines in muscle cells

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonCytoplasm, myofibril, sarcomere, Z line

MECANISMO DE DOENÇA

Myopathy, myofibrillar, 3

A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM3 is characterized by progressive skeletal muscle weakness greater distally than proximally, tight heel cords, hyporeflexia, cardiomyopathy and peripheral neuropathy in some patients. Affected muscle exhibits disorganization and streaming of the Z-line, presence of large hyaline structures, excessive accumulation of myotilin and other ectopically expressed proteins and prominent congophilic deposits.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
602.6 TPM
Nervo tibial
12.9 TPM
Cólon sigmoide
10.7 TPM
Cervix Ectocervix
9.3 TPM
Esôfago - Muscular
9.1 TPM
OUTRAS DOENÇAS (1)
myofibrillar myopathy 3
HGNC:12399UniProt:Q9UBF9
TRIM32E3 ubiquitin-protein ligase TRIM32Disease-causing germline mutation(s) inTolerante
FUNÇÃO

E3 ubiquitin ligase that plays a role in various biological processes including neural stem cell differentiation, innate immunity, inflammatory resonse and autophagy (PubMed:19349376, PubMed:31123703). Plays a role in virus-triggered induction of IFN-beta and TNF by mediating the ubiquitination of STING1. Mechanistically, targets STING1 for 'Lys-63'-linked ubiquitination which promotes the interaction of STING1 with TBK1 (PubMed:22745133). Regulates bacterial clearance and promotes autophagy in

LOCALIZAÇÃO

CytoplasmMitochondrionEndoplasmic reticulum

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationRegulation of innate immune responses to cytosolic DNA
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 8

An autosomal recessive degenerative myopathy characterized by pelvic girdle, shoulder girdle and quadriceps muscle weakness. Clinical phenotype and severity are highly variable. Disease progression is slow and most patients remain ambulatory into the sixth decade of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
28.5 TPM
Fibroblastos
24.7 TPM
Cerebelo
21.4 TPM
Útero
20.4 TPM
Cervix Endocervix
19.7 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2HBardet-Biedl syndrome 11Bardet-Biedl syndrome
HGNC:16380UniProt:Q13049
PLECPlectinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Interlinks intermediate filaments with microtubules and microfilaments and anchors intermediate filaments to desmosomes or hemidesmosomes. Could also bind muscle proteins such as actin to membrane complexes in muscle. May be involved not only in the filaments network, but also in the regulation of their dynamics. Structural component of muscle. Isoform 9 plays a major role in the maintenance of myofiber integrity

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell junction, hemidesmosomeCell projection, podosome

VIAS BIOLÓGICAS (3)
Caspase-mediated cleavage of cytoskeletal proteinsType I hemidesmosome assemblyAssembly of collagen fibrils and other multimeric structures
MECANISMO DE DOENÇA

Epidermolysis bullosa simplex 5C, with pyloric atresia

A form of epidermolysis bullosa, a genodermatosis characterized by recurrent blistering, fragility of the skin and mucosal epithelia, and erosions caused by minor mechanical trauma. EBS5C is an autosomal recessive disorder characterized by severe skin blistering at birth and congenital pyloric atresia. Death usually occurs in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
241.5 TPM
Fibroblastos
212.0 TPM
Músculo esquelético
151.2 TPM
Aorta
144.6 TPM
Artéria tibial
138.0 TPM
OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Qepidermolysis bullosa simplex 5A, Ogna typeepidermolysis bullosa simplex 5C, with pyloric atresiaepidermolysis bullosa simplex 5B, with muscular dystrophy
HGNC:9069UniProt:Q15149
TMEM43Transmembrane protein 43Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May have an important role in maintaining nuclear envelope structure by organizing protein complexes at the inner nuclear membrane. Required for retaining emerin at the inner nuclear membrane (By similarity). Plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26 (PubMed:32614325). In addition, functions as a critical signaling component in mediating NF-kappa-B activation by acting downstream of EGFR and upstream of CARD10 (PubMed:27991

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus inner membraneCell membrane

MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 5

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
247.5 TPM
Artéria tibial
212.8 TPM
Útero
192.2 TPM
Artéria coronária
180.6 TPM
Fibroblastos
178.4 TPM
OUTRAS DOENÇAS (7)
Emery-Dreifuss muscular dystrophy 7, autosomal dominantarrhythmogenic right ventricular dysplasia 5auditory neuropathy, autosomal dominant 3familial isolated arrhythmogenic ventricular dysplasia, left dominant form
HGNC:28472UniProt:Q9BTV4
TCAPTelethoninDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Muscle assembly regulating factor. Mediates the antiparallel assembly of titin (TTN) molecules at the sarcomeric Z-disk

LOCALIZAÇÃO

Cytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (1)
Striated Muscle Contraction
MECANISMO DE DOENÇA

Cardiomyopathy, familial hypertrophic, 25

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
2504.5 TPM
Coração - Ventrículo esquerdo
1812.2 TPM
Coração - Átrio
1252.5 TPM
Cerebelo
14.4 TPM
Cérebro - Hemisfério cerebelar
12.1 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2Ghypertrophic cardiomyopathy 25familial isolated dilated cardiomyopathy
HGNC:11610UniProt:O15273
KIF21AKinesin-like protein KIF21ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Processive microtubule plus-end directed motor protein involved in neuronal axon guidance. Is recruited by KANK1 to cortical microtubule stabilizing complexes (CMSCs) at focal adhesions (FAs) rims where it promotes microtubule capture and stability. Controls microtubule polymerization rate at axonal growth cones and suppresses microtubule growth without inducing microtubule disassembly once it reaches the cell cortex

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasm, cell cortexCell projection, axonCell projection, dendriteCell projection, growth cone

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 1

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Patients affected by congenital fibrosis of extraocular muscles type 1 show an absence of the superior division of the oculomotor nerve (cranial nerve III) and corresponding oculomotor subnuclei.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
44.0 TPM
Cerebelo
34.5 TPM
Brain Frontal Cortex BA9
31.4 TPM
Hipotálamo
25.5 TPM
Brain Spinal cord cervical c-1
23.1 TPM
OUTRAS DOENÇAS (3)
congenital fibrosis of extraocular muscles type 1congenital fibrosis of extraocular musclesfetal akinesia deformation sequence 1
HGNC:19349UniProt:Q7Z4S6
TUBB3Tubulin beta-3 chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tubulin is the major constituent of microtubules, protein filaments consisting of alpha- and beta-tubulin heterodimers (PubMed:34996871, PubMed:38305685, PubMed:38609661). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:34996871, PubMed:38305685, PubMed:38609661). Below the cap, alpha-beta tubulin heterodimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871, PubMed:38609661). TUBB3 plays a cr

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, growth coneCell projection, lamellipodiumCell projection, filopodium

VIAS BIOLÓGICAS (10)
HCMV Early EventsPKR-mediated signalingGap junction assemblyAggrephagyAssembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 3A

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 3 presents as a non-progressive, autosomal dominant disorder with variable expression. Patients may be bilaterally or unilaterally affected, and their oculo-motility defects range from complete ophthalmoplegia (with the eyes fixed in a hypo- and exotropic position), to mild asymptomatic restrictions of ocular movement. Ptosis, refractive error, amblyopia, and compensatory head positions are associated with the more severe forms of the disorder. In some cases, the ocular phenotype is accompanied by additional features including developmental delay, corpus callosum agenesis, basal ganglia dysmorphism, facial weakness, polyneuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Hipotálamo
143.8 TPM
Brain Frontal Cortex BA9
123.1 TPM
Córtex cerebral
102.0 TPM
Cérebro - Hemisfério cerebelar
101.2 TPM
Cerebelo
101.0 TPM
OUTRAS DOENÇAS (4)
fibrosis of extraocular muscles, congenital, 3A, with or without extraocular involvementcomplex cortical dysplasia with other brain malformations 1congenital fibrosis of extraocular musclestubulinopathy-associated dysgyria
HGNC:20772UniProt:Q13509
TOR1AIP1Torsin-1A-interacting protein 1Candidate gene tested inTolerante
FUNÇÃO

Required for nuclear membrane integrity. Induces TOR1A and TOR1B ATPase activity and is required for their location on the nuclear membrane. Binds to A- and B-type lamins. Possible role in membrane attachment and assembly of the nuclear lamina

LOCALIZAÇÃO

Nucleus inner membraneNucleus envelopeNucleus

VIAS BIOLÓGICAS (2)
RHOF GTPase cycleRHOD GTPase cycle
MECANISMO DE DOENÇA

Myopathy, autosomal recessive, with rigid spine and distal joint contractures

An autosomal recessive degenerative myopathy characterized by muscle weakness initially involving the proximal lower limbs, followed by distal upper and lower limb muscle weakness and atrophy. Other features include joint contractures, rigid spine, and restricted pulmonary function. Cardiac involvement has been observed in some patients. Disease onset is in the first or second decades of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
39.4 TPM
Esôfago - Muscular
35.9 TPM
Aorta
35.5 TPM
Esôfago - Junção
35.5 TPM
Cólon sigmoide
35.2 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
autosomal recessive limb-girdle muscular dystrophy type 2Y
HGNC:29456UniProt:Q5JTV8
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus plays a critical role in cellular cholesterol homeostasis (PubMed:21357570, PubMed:2991281, PubMed:36745799, PubMed:6995544). HMGCR is the main target of statins, a class of cholesterol-lowering drugs (PubMed:11349148, PubMed:18540668, PubMed:36745799)

LOCALIZAÇÃO

Endoplasmic reticulum membranePeroxisome membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 28

An autosomal recessive form of limb girdle muscular dystrophy, a group of genetically heterogeneous muscular disorders that share proximal muscle weakness as the major attribute. Most limb girdle muscular dystrophies present with elevated creatinine kinase and myopathic electromyographic features. Disease is usually progressive to a variable degree, ranging from minor disability to complete inability to ambulate, and can involve the large proximal muscles, as well as axial and facial muscles. Different disease forms may exhibit skeletal muscle hypertrophy, kyphoscoliosis, and contractures or involve other muscle groups and manifest with distal weakness, cardiomyopathy, dysphagia, and respiratory difficulties. LGMDR28 is characterized by progressive muscle weakness affecting the proximal and axial muscles of the upper and lower limbs, and highly variable age at onset. Most patients have limited ambulation or become wheelchair-bound within a few decades, and respiratory insufficiency commonly occurs.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
80.4 TPM
Skin Sun Exposed Lower leg
73.8 TPM
Linfócitos
66.2 TPM
Esôfago - Mucosa
63.8 TPM
Vagina
42.9 TPM
OUTRAS DOENÇAS (1)
muscular dystrophy, limb-girdle, autosomal recessive 28
HGNC:5006UniProt:P04035
RILPL1RILP-like protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in the regulation of cell shape and polarity (By similarity). Plays a role in cellular protein transport, including protein transport away from primary cilia (By similarity). Neuroprotective protein, which acts by sequestring GAPDH in the cytosol and prevent the apoptotic function of GAPDH in the nucleus (By similarity). Competes with SIAH1 for binding GAPDH (By similarity). Does not regulate lysosomal morphology and distribution (PubMed:14668488). Binds to RAB10 following LRRK2-med

LOCALIZAÇÃO

Cytoplasm, cytosolCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centrioleCytoplasm, cytoskeleton, cilium basal body

MECANISMO DE DOENÇA

Oculopharyngodistal myopathy 4

A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM4 is an autosomal dominant form characterized by slow progression and onset of symptoms in the second or third decades.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Átrio
27.2 TPM
Aorta
22.7 TPM
Coração - Ventrículo esquerdo
19.9 TPM
Músculo esquelético
19.7 TPM
Tireoide
19.6 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
oculopharyngodistal myopathy 4oculopharyngodistal myopathy
HGNC:26814UniProt:Q5EBL4
POMT1Protein O-mannosyl-transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
73.9 TPM
Cerebelo
65.0 TPM
Cérebro - Hemisfério cerebelar
61.3 TPM
Pituitária
32.9 TPM
Ovário
27.8 TPM
OUTRAS DOENÇAS (8)
autosomal recessive limb-girdle muscular dystrophy type 2Kmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1muscle-eye-brain disease
HGNC:9202UniProt:Q9Y6A1
FHL1Four and a half LIM domains protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May have an involvement in muscle development or hypertrophy

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytosol

MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 6, X-linked

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
2024.8 TPM
Artéria tibial
1151.4 TPM
Aorta
1150.7 TPM
Esôfago - Junção
873.7 TPM
Esôfago - Muscular
862.0 TPM
OUTRAS DOENÇAS (7)
X-linked myopathy with postural muscle atrophyX-linked scapuloperoneal muscular dystrophymyopathy, reducing body, X-linked, early-onset, severemyopathy, reducing body, X-linked, childhood-onset
HGNC:3702UniProt:Q13642
POMKProtein O-mannose kinaseCandidate gene tested inTolerante
FUNÇÃO

Protein O-mannose kinase that specifically mediates phosphorylation at the 6-position of an O-mannose of the trisaccharide (N-acetylgalactosamine (GalNAc)-beta-1,3-N-acetylglucosamine (GlcNAc)-beta-1,4-mannose) to generate phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-1,3-N-acetylglucosamine-beta-1,4-(phosphate-6-)mannose). Phosphorylated O-mannosyl trisaccharide is a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like d

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
6.4 TPM
Fibroblastos
5.9 TPM
Cérebro - Hemisfério cerebelar
3.0 TPM
Cerebelo
2.7 TPM
Testículo
2.3 TPM
OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12limb-girdle muscular dystrophy due to POMK deficiencyobsolete congenital muscular dystrophy with cerebellar involvementmuscular dystrophy-dystroglycanopathy, type A
HGNC:26267UniProt:Q9H5K3
PHOX2APaired mesoderm homeobox protein 2ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in regulating the specificity of expression of the catecholamine biosynthetic genes. Acts as a transcription activator/factor. Could maintain the noradrenergic phenotype

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 2

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 2 may result from the defective development of the oculomotor (nIII), trochlear (nIV) and abducens (nVI) cranial nerve nuclei.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
2.7 TPM
Testículo
1.4 TPM
Esôfago - Muscular
1.4 TPM
Cólon transverso
1.3 TPM
Esôfago - Junção
1.0 TPM
OUTRAS DOENÇAS (2)
fibrosis of extraocular muscles, congenital, 2congenital fibrosis of extraocular muscles
HGNC:691UniProt:O14813
HNRNPDLHeterogeneous nuclear ribonucleoprotein D-likeDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Acts as a transcriptional regulator. Promotes transcription repression. Promotes transcription activation in differentiated myotubes (By similarity). Binds to double- and single-stranded DNA sequences. Binds to the transcription suppressor CATR sequence of the COX5B promoter (By similarity). Binds with high affinity to RNA molecules that contain AU-rich elements (AREs) found within the 3'-UTR of many proto-oncogenes and cytokine mRNAs. Binds both to nuclear and cytoplasmic poly(A) mRNAs. Binds t

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal dominant 3

An autosomal dominant degenerative myopathy characterized by slowly progressive wasting and weakness of the proximal muscles of arms and legs around the pelvic or shoulder girdles, elevated creatine kinase levels and dystrophic features on muscle biopsy. LGMDD3 is characterized by a mild late-onset and is associated with progressive fingers and toes flexion limitation. Affected individuals may also develop cataracts before age 50.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
308.8 TPM
Útero
294.6 TPM
Nervo tibial
282.6 TPM
Cervix Endocervix
277.1 TPM
Cervix Ectocervix
271.0 TPM
OUTRAS DOENÇAS (1)
autosomal dominant limb-girdle muscular dystrophy type 1G
HGNC:5037UniProt:O14979
POGLUT1Protein O-glucosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Dual specificity glycosyltransferase that catalyzes the transfer of glucose and xylose from UDP-glucose and UDP-xylose, respectively, to a serine residue found in the consensus sequence of C-X-S-X-P-C (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Specifically targets extracellular EGF repeats of protein such as CRB2, F7, F9 and NOTCH2 (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Acts as a positive regulator of Not

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (1)
Pre-NOTCH Processing in the Endoplasmic Reticulum
MECANISMO DE DOENÇA

Dowling-Degos disease 4

A form of Dowling-Degos disease, a genodermatosis manifesting with postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. DDD4 is characterized by prominent involvement of non-flexural skin areas.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
18.8 TPM
Linfócitos
18.3 TPM
Cervix Ectocervix
17.1 TPM
Cervix Endocervix
16.6 TPM
Baço
16.2 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2R1Dowling-Degos disease 4Dowling-Degos disease
HGNC:22954UniProt:Q8NBL1
POPDC1Popeye domain-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Cell adhesion molecule involved in the establishment and/or maintenance of cell integrity. Involved in the formation and regulation of the tight junction (TJ) paracellular permeability barrier in epithelial cells (PubMed:16188940). Plays a role in VAMP3-mediated vesicular transport and recycling of different receptor molecules through its interaction with VAMP3. Plays a role in the regulation of cell shape and movement by modulating the Rho-family GTPase activity through its interaction with ARH

LOCALIZAÇÃO

Lateral cell membraneCell junction, tight junctionMembraneCell membrane, sarcolemmaMembrane, caveola

MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 25

An autosomal recessive muscular disorder characterized by slowly progressive onset of proximal lower limb weakness in adulthood, syncopal episodes, and markedly increased serum creatine kinase, which can increase further after strenuous exercise.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
autosomal recessive limb-girdle muscular dystrophy type 2X
HGNC:1152UniProt:Q8NE79
POPDC3Popeye domain-containing protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in the maintenance of heart function mediated, at least in part, through cAMP-binding. May play a role in the regulation of KCNK2/TREK-1-mediated current amplitude (PubMed:31610034)

LOCALIZAÇÃO

Membrane

MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 26

An autosomal recessive muscular disorder characterized by adult onset of weakness and atrophy of proximal limb muscles, elevated serum creatine kinase levels, and dystrophic findings on muscle biopsy. There is no cardiac or respiratory involvement.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
82.8 TPM
Fibroblastos
21.8 TPM
Coração - Ventrículo esquerdo
18.0 TPM
Coração - Átrio
14.9 TPM
Brain Frontal Cortex BA9
14.1 TPM
OUTRAS DOENÇAS (1)
muscular dystrophy, limb-girdle, autosomal recessive 26
HGNC:HGNC:17649UniProt:Q9HBV1
HNRNPA2B1Heterogeneous nuclear ribonucleoproteins A2/B1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs (PubMed:19099192). Forms

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmCytoplasmCytoplasmic granuleSecreted, extracellular exosome

VIAS BIOLÓGICAS (1)
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
889.4 TPM
Linfócitos
838.4 TPM
Útero
763.3 TPM
Cervix Endocervix
691.2 TPM
Cervix Ectocervix
681.9 TPM
OUTRAS DOENÇAS (3)
oculopharyngeal muscular dystrophy 2inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2inclusion body myopathy with Paget disease of bone and frontotemporal dementia
HGNC:5033UniProt:P22626
PABPN1Polyadenylate-binding protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Involved in the 3'-end formation of mRNA precursors (pre-mRNA) by the addition of a poly(A) tail of 200-250 nt to the upstream cleavage product (By similarity). Stimulates poly(A) polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation reaction and also controls the poly(A) tail length (By similarity). Increases the affinity of poly(A) polymerase for RNA (By similarity). Is also present at various stages of mRNA metabolism including nucleocytoplasmic trafficking and nonsense-m

LOCALIZAÇÃO

NucleusCytoplasmNucleus speckle

VIAS BIOLÓGICAS (7)
Inhibition of Host mRNA Processing and RNA SilencingmRNA 3'-end processingDengue Virus-Host InteractionsProcessing of Intronless Pre-mRNAsRNA Polymerase II Transcription Termination
MECANISMO DE DOENÇA

Oculopharyngeal muscular dystrophy 1

An autosomal dominant, late-onset, slowly progressive myopathy characterized by eyelid ptosis, dysphagia and, sometimes by other cranial and limb-muscle involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
342.6 TPM
Cerebelo
333.3 TPM
Fallopian Tube
310.8 TPM
Testículo
307.5 TPM
Útero
292.1 TPM
OUTRAS DOENÇAS (2)
oculopharyngeal muscular dystrophy 1oculopharyngeal muscular dystrophy
HGNC:8565UniProt:Q86U42
SGCAAlpha-sarcoglycanCandidate gene tested inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 3

An autosomal recessive degenerative myopathy characterized by progressive muscle wasting from early childhood with loss of independent ambulation by teenage years. Muscle biopsy shows necrosis, decreased immunostaining for alpha sarcoglycan, and adhalin deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
227.0 TPM
Aorta
223.0 TPM
Artéria tibial
162.2 TPM
Artéria coronária
146.7 TPM
Esôfago - Junção
94.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive limb-girdle muscular dystrophyautosomal recessive limb-girdle muscular dystrophy type 2D
HGNC:10805UniProt:Q16586
SGCDDelta-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 6

An autosomal recessive degenerative myopathy initially affecting the proximal limb girdle musculature. Muscle from patients shows a complete loss of delta-sarcoglycan as well as of the others components of the sarcoglycan complex.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
26.6 TPM
Aorta
20.2 TPM
Músculo esquelético
15.2 TPM
Esôfago - Junção
14.2 TPM
Coração - Átrio
12.8 TPM
OUTRAS DOENÇAS (4)
autosomal recessive limb-girdle muscular dystrophy type 2Fdilated cardiomyopathy 1Lautosomal recessive limb-girdle muscular dystrophyfamilial isolated dilated cardiomyopathy
HGNC:10807UniProt:Q92629
GMPPBMannose-1-phosphate guanylyltransferase catalytic subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the GMPPA-GMPPB mannose-1-phosphate guanylyltransferase complex (PubMed:33986552). Catalyzes the formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and glycolipids (PubMed:33986552). Can catalyze the reverse reaction in vitro (PubMed:33986552). Together with GMPPA regulates GDP-alpha-D-mannose levels (PubMed:33986552)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
56.4 TPM
Tireoide
41.5 TPM
Linfócitos
39.6 TPM
Próstata
37.0 TPM
Glândula salivar
32.5 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14autosomal recessive limb-girdle muscular dystrophy type 2Tmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14muscle-eye-brain disease
HGNC:22932UniProt:Q9Y5P6
NOTCH2NLCNotch homolog 2 N-terminal-like protein CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Human-specific protein that promotes neural progenitor proliferation and evolutionary expansion of the brain neocortex by regulating the Notch signaling pathway (PubMed:29561261, PubMed:29856954, PubMed:29856955). Able to promote neural progenitor self-renewal, possibly by down-regulating neuronal differentiation genes, thereby delaying the differentiation of neuronal progenitors and leading to an overall final increase in neuronal production (PubMed:29856954). Acts by enhancing the Notch signal

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Expression of NOTCH2NL genesNOTCH2 Activation and Transmission of Signal to the Nucleus
MECANISMO DE DOENÇA

Neuronal intranuclear inclusion disease

An autosomal dominant, slowly progressive, neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in the central and peripheral nervous system, and also in the visceral organs. Clinical manifestations are variable and include pyramidal and extrapyramidal symptoms, cerebellar ataxia, cognitive decline and dementia, peripheral neuropathy, and autonomic dysfunction.

INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
oculopharyngodistal myopathy 3tremor, hereditary essential, 6neuronal intranuclear inclusion diseaseoculopharyngodistal myopathy
HGNC:53924UniProt:P0DPK4
LMNAPrelamin-A/CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:2188730, PubMed:22431096, PubMed:2344612, PubMed:23666920, PubMed:24741066, PubMed:31434876, PubMed:

LOCALIZAÇÃO

Nucleus laminaNucleus envelopeNucleus, nucleoplasmNucleus matrixNucleus speckle

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 2, autosomal dominant

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
392.7 TPM
Aorta
300.6 TPM
Skin Not Sun Exposed Suprapubic
297.7 TPM
Skin Sun Exposed Lower leg
272.6 TPM
Útero
255.8 TPM
OUTRAS DOENÇAS (23)
restrictive dermopathy 2familial partial lipodystrophy, Dunnigan typedilated cardiomyopathy-hypergonadotropic hypogonadism syndromemandibuloacral dysplasia with type A lipodystrophy
HGNC:6636UniProt:P02545
SNUPNSnurportin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions as an U snRNP-specific nuclear import adapter. Involved in the trimethylguanosine (m3G)-cap-dependent nuclear import of U snRNPs. Binds specifically to the terminal m3G-cap U snRNAs

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
snRNP Assembly
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 29

An autosomal recessive form of limb girdle muscular dystrophy, a group of genetically heterogeneous muscular disorders that share proximal muscle weakness as the major attribute. Most limb girdle muscular dystrophies present with elevated creatinine kinase and myopathic electromyographic features. Disease is usually progressive to a variable degree, ranging from minor disability to complete inability to ambulate, and can involve the large proximal muscles, as well as axial and facial muscles. Different disease forms may exhibit skeletal muscle hypertrophy, kyphoscoliosis, and contractures or involve other muscle groups and manifest with distal weakness, cardiomyopathy, dysphagia, and respiratory difficulties. LGMDR29 is characterized by muscle weakness predominantly affecting the proximal lower limbs, although upper limb involvement also occurs. Additional features include joint contractures, spinal abnormalities, and significant restrictive ventilatory dysfunction. In rare cases, central nervous system involvement has been reported, including cataracts, developmental delay, and brain imaging abnormalities.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
40.0 TPM
Nervo tibial
25.2 TPM
Ovário
24.3 TPM
Fallopian Tube
23.7 TPM
Cervix Endocervix
23.4 TPM
OUTRAS DOENÇAS (1)
muscular dystrophy, limb-girdle, autosomal recessive 29
HGNC:HGNC:14245UniProt:O95149
EMDEmerinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Stabilizes and promotes the formation of a nuclear actin cortical network. Stimulates actin polymerization in vitro by binding and stabilizing the pointed end of growing filaments. Inhibits beta-catenin activity by preventing its accumulation in the nucleus. Acts by influencing the nuclear accumulation of beta-catenin through a CRM1-dependent export pathway. Links centrosomes to the nuclear envelope via a microtubule association. Required for proper localization of non-farnesylated prelamin-A/C.

LOCALIZAÇÃO

Nucleus inner membraneNucleus outer membrane

VIAS BIOLÓGICAS (3)
Initiation of Nuclear Envelope (NE) ReformationNuclear Envelope BreakdownDepolymerization of the Nuclear Lamina
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 1, X-linked

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
236.6 TPM
Artéria tibial
203.8 TPM
Útero
199.2 TPM
Fallopian Tube
185.4 TPM
Cervix Endocervix
177.1 TPM
OUTRAS DOENÇAS (2)
Emery-Dreifuss muscular dystrophy 1, X-linkedX-linked Emery-Dreifuss muscular dystrophy
HGNC:3331UniProt:P50402
GIPC1PDZ domain-containing protein GIPC1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in G protein-linked signaling

LOCALIZAÇÃO

CytoplasmMembrane

VIAS BIOLÓGICAS (4)
FGFR1b ligand binding and activationFGFR1c ligand binding and activationTGFBR3 regulates FGF2 signalingTGFBR3 regulates TGF-beta signaling
MECANISMO DE DOENÇA

Oculopharyngodistal myopathy 2

A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM2 inheritance pattern is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
340.8 TPM
Vagina
186.9 TPM
Skin Sun Exposed Lower leg
172.1 TPM
Skin Not Sun Exposed Suprapubic
163.3 TPM
Pulmão
111.3 TPM
OUTRAS DOENÇAS (2)
oculopharyngodistal myopathy 2oculopharyngodistal myopathy
HGNC:1226UniProt:O14908
TRAPPC11Trafficking protein particle complex subunit 11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in endoplasmic reticulum to Golgi apparatus trafficking at a very early stage

LOCALIZAÇÃO

Golgi apparatusGolgi apparatus, cis-Golgi network

VIAS BIOLÓGICAS (1)
RAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 18

A form of limb-girdle muscular dystrophy characterized by proximal muscle weakness with childhood onset, resulting in gait abnormalities and scapular winging. Serum creatine kinase is increased. A subset of patients may show a hyperkinetic movement disorder with chorea, ataxia, or dystonia and global developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
33.7 TPM
Cérebro - Hemisfério cerebelar
31.5 TPM
Linfócitos
30.9 TPM
Nervo tibial
29.6 TPM
Cerebelo
29.4 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type R18intellectual disability-hyperkinetic movement-truncal ataxia syndrometriple-A syndrome
HGNC:25751UniProt:Q7Z392
SGCGGamma-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 5

An autosomal recessive degenerative myopathy characterized by rapidly progressive muscle wasting from early childhood with loss of independent ambulation around age 12 years, dystrophic pattern on muscle biopsy, absence of gamma-sarcoglycan and normal dystrophin immunostaining.

EXPRESSÃO TECIDUAL(Tecido-específico)
Coração - Ventrículo esquerdo
59.2 TPM
Músculo esquelético
56.9 TPM
Coração - Átrio
50.8 TPM
Aorta
6.8 TPM
Pulmão
6.7 TPM
OUTRAS DOENÇAS (2)
autosomal recessive limb-girdle muscular dystrophy type 2Cautosomal recessive limb-girdle muscular dystrophy
HGNC:10809UniProt:Q13326
POMGNT2Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular prote

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
98.5 TPM
Cerebelo
94.9 TPM
Cérebro - Hemisfério cerebelar
94.0 TPM
Ovário
60.0 TPM
Fallopian Tube
58.8 TPM
OUTRAS DOENÇAS (3)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8muscular dystrophy-dystroglycanopathy, type A
HGNC:25902UniProt:Q8NAT1
LAMA2Laminin subunit alpha-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (8)
MET activates PTK2 signalingDevelopmental Lineage of Pancreatic Ductal CellsAttachment of bacteria to epithelial cellsLaminin interactionsEGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Merosin-deficient congenital muscular dystrophy 1A

Characterized by difficulty walking, hypotonia, proximal weakness, hyporeflexia, and white matter hypodensity on MRI.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
116.5 TPM
Nervo tibial
92.9 TPM
Fallopian Tube
80.1 TPM
Artéria coronária
63.2 TPM
Fibroblastos
62.6 TPM
OUTRAS DOENÇAS (2)
congenital merosin-deficient muscular dystrophy 1Amuscular dystrophy, limb-girdle, autosomal recessive 23
HGNC:6482UniProt:P24043
TTNTitinDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Key component in the assembly and functioning of vertebrate striated muscles. By providing connections at the level of individual microfilaments, it contributes to the fine balance of forces between the two halves of the sarcomere. The size and extensibility of the cross-links are the main determinants of sarcomere extensibility properties of muscle. In non-muscle cells, seems to play a role in chromosome condensation and chromosome segregation during mitosis. Might link the lamina network to ch

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Platelet degranulation
MECANISMO DE DOENÇA

Myopathy, myofibrillar, 9, with early respiratory failure

An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
358.5 TPM
Coração - Ventrículo esquerdo
66.8 TPM
Coração - Átrio
56.9 TPM
Testículo
1.6 TPM
Pulmão
1.0 TPM
OUTRAS DOENÇAS (14)
autosomal recessive limb-girdle muscular dystrophy type 2Jmyopathy, myofibrillar, 9, with early respiratory failureearly-onset myopathy with fatal cardiomyopathydilated cardiomyopathy 1G
HGNC:12403UniProt:Q8WZ42
CNBPCCHC-type zinc finger nucleic acid binding proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Single-stranded DNA-binding protein that preferentially binds to the sterol regulatory element (SRE) sequence 5'-GTGCGGTG-3', and thereby mediates transcriptional repression (PubMed:2562787). Has a role as transactivator of the Myc promoter (By similarity). Binds single-stranded RNA in a sequence-specific manner (By similarity) Binds G-rich elements in target mRNA coding sequences (PubMed:28329689). Prevents G-quadruplex structure formation in vitro, suggesting a role in supporting translation b

LOCALIZAÇÃO

NucleusCytoplasmEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
SARS-CoV-2 activates/modulates innate and adaptive immune responses
MECANISMO DE DOENÇA

Dystrophia myotonica 2

A multisystem disease characterized by the association of proximal muscle weakness with myotonia, cardiac manifestations and cataract. Additional features can include hyperhidrosis, testicular atrophy, insulin resistance and diabetes and central nervous system anomalies in rare cases.

OUTRAS DOENÇAS (1)
myotonic dystrophy type 2
HGNC:13164UniProt:P62633
COL12A1Collagen alpha-1(XII) chainCandidate gene tested inAltamente restrito
FUNÇÃO

Type XII collagen interacts with type I collagen-containing fibrils, the COL1 domain could be associated with the surface of the fibrils, and the COL2 and NC3 domains may be localized in the perifibrillar matrix

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (3)
Collagen degradationAssembly of collagen fibrils and other multimeric structuresCollagen biosynthesis and modifying enzymes
MECANISMO DE DOENÇA

Ullrich congenital muscular dystrophy 2

A form of Ullrich congenital muscular dystrophy, a disease characterized by generalized muscle weakness and striking hypermobility of distal joints in conjunction with variable contractures of more proximal joints and normal intelligence. Additional findings may include kyphoscoliosis, protruded calcanei, and follicular hyperkeratosis (rough skin). More severely affected patients manifest at birth and never achieve independent ambulation, while patients with milder phenotypes might maintain ambulation into adulthood. UCMD2 is a severe, autosomal recessive form with onset at birth.

OUTRAS DOENÇAS (4)
Ullrich congenital muscular dystrophy 2Bethlem myopathy 2Bethlem myopathyUllrich congenital muscular dystrophy
HGNC:2188UniProt:Q99715
ABCD3ATP-binding cassette sub-family D member 3Candidate gene tested inRestrito
FUNÇÃO

Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that catalyzes the transport of long-chain fatty acids (LCFA)-CoA, dicarboxylic acids-CoA, long-branched-chain fatty acids-CoA and bile acids from the cytosol to the peroxisome lumen for beta-oxydation (PubMed:11248239, PubMed:24333844, PubMed:25168382, PubMed:29397936). Has fatty acyl-CoA thioesterase and ATPase activities (PubMed:29397936). Probably hydrolyzes fatty acyl-CoAs into free fatty acids pr

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (2)
ABC transporters in lipid homeostasisClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Congenital bile acid synthesis defect 5

An autosomal recessive disorder characterized by hepatosplenomegaly, hepatic fibrosis, progressive liver failure, and accumulation of peroxisomal C27-bile acid intermediates in plasma.

OUTRAS DOENÇAS (2)
congenital bile acid synthesis defect 5oculopharyngodistal myopathy
HGNC:67UniProt:P28288
COL25A1Collagen alpha-1(XXV) chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Inhibits fibrillization of amyloid-beta peptide during the elongation phase. Has also been shown to assemble amyloid fibrils into protease-resistant aggregates. Binds heparin

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 5

An ocular motility disorder characterized by congenital dysinnervation of various cranial nerves to ocular muscles. Clinical features are ophthalmoplegia, anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head.

INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (4)
fibrosis of extraocular muscles, congenital, 5ptosis, hereditary congenital, 1arthrogryposis multiplex congenita 2, neurogenic typecongenital fibrosis of extraocular muscles
HGNC:18603UniProt:Q9BXS0
COL6A3Collagen alpha-3(VI) chainCandidate gene tested inRestrito
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Bethlem myopathy 1C

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. BTHLM1C inheritance is autosomal dominant.

OUTRAS DOENÇAS (6)
dystonia 27Ullrich congenital muscular dystrophy 1CBethlem myopathy 1Cintermediate collagen VI-related muscular dystrophy
HGNC:2213UniProt:P12111
DNMT3BDNA (cytosine-5)-methyltransferase 3BDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. DNA methylation is coordinated with methylation of histones. May preferentially methylates nucleosomal DNA within the nucleosome core region. May function as transcriptional co-repressor by associating with CBX4 and independently of DNA methylation. Seems to be involved in gene silencing (By similarity). In association with DNMT1 and via the recruitment of CTCFL/BOR

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (5)
Defective pyroptosisPRC2 methylates histones and DNADNA methylationNoRC negatively regulates rRNA expressionSUMOylation of DNA methylation proteins
MECANISMO DE DOENÇA

Immunodeficiency-centromeric instability-facial anomalies syndrome 1

A rare disorder characterized by a variable immunodeficiency resulting in recurrent infections, facial anomalies, and branching of chromosomes 1, 9, and 16. Other variable symptoms include growth retardation, failure to thrive, and psychomotor retardation. Laboratory studies show limited hypomethylation of DNA in a small fraction of the genome in some, but not all, patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
12.8 TPM
Cerebelo
5.4 TPM
Cérebro - Hemisfério cerebelar
5.3 TPM
Skin Sun Exposed Lower leg
5.1 TPM
Skin Not Sun Exposed Suprapubic
4.9 TPM
OUTRAS DOENÇAS (4)
facioscapulohumeral muscular dystrophy 4, digenicimmunodeficiency-centromeric instability-facial anomalies syndrome 1immunodeficiency-centromeric instability-facial anomalies syndromefacioscapulohumeral muscular dystrophy
HGNC:2979UniProt:Q9UBC3
COL6A1Collagen alpha-1(VI) chainCandidate gene tested inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1A

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (5)
Ullrich congenital muscular dystrophy 1ABethlem myopathy 1Aintermediate collagen VI-related muscular dystrophyBethlem myopathy
HGNC:2211UniProt:P12109
COL6A2Collagen alpha-2(VI) chainCandidate gene tested inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixMembrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1B

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (6)
Ullrich congenital muscular dystrophy 1BmyosclerosisBethlem myopathy 1Bintermediate collagen VI-related muscular dystrophy
HGNC:2212UniProt:P12110
CAPN3Calpain-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium-regulated non-lysosomal thiol-protease. Proteolytically cleaves CTBP1 at 'His-409'. Mediates, with UTP25, the proteasome-independent degradation of p53/TP53 (PubMed:23357851, PubMed:27657329)

LOCALIZAÇÃO

CytoplasmNucleus, nucleolus

VIAS BIOLÓGICAS (1)
Degradation of the extracellular matrix
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 1

An autosomal recessive degenerative myopathy characterized by progressive symmetrical atrophy and weakness of the proximal limb muscles and elevated serum creatine kinase. The symptoms usually begin during the first two decades of life, and the disease gradually worsens, often resulting in loss of walking ability 10 or 20 years after onset.

OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2Amuscular dystrophy, limb-girdle, autosomal dominant 4autosomal recessive limb-girdle muscular dystrophy
HGNC:1480UniProt:P20807
DMDDystrophinCandidate gene tested inAltamente restrito
FUNÇÃO

Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonPostsynaptic cell membrane

VIAS BIOLÓGICAS (3)
Formation of the dystrophin-glycoprotein complex (DGC)Non-integrin membrane-ECM interactionsStriated Muscle Contraction
MECANISMO DE DOENÇA

Duchenne muscular dystrophy

Most common form of muscular dystrophy; a sex-linked recessive disorder. It typically presents in boys aged 3 to 7 year as proximal muscle weakness causing waddling gait, toe-walking, lordosis, frequent falls, and difficulty in standing up and climbing up stairs. The pelvic girdle is affected first, then the shoulder girdle. Progression is steady and most patients are confined to a wheelchair by age of 10 or 12. Flexion contractures and scoliosis ultimately occur. About 50% of patients have a lower IQ than their genetic expectations would suggest. There is no treatment.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
44.5 TPM
Artéria tibial
28.2 TPM
Aorta
27.2 TPM
Cólon sigmoide
25.6 TPM
Músculo esquelético
23.1 TPM
OUTRAS DOENÇAS (6)
Duchenne muscular dystrophyBecker muscular dystrophydilated cardiomyopathy 3Bsymptomatic form of muscular dystrophy of Duchenne and Becker in female carriers
HGNC:2928UniProt:P11532
DYSFDysferlinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress (By similarity)

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasmic vesicle membraneCell membraneLate endosome membrane

VIAS BIOLÓGICAS (1)
Smooth Muscle Contraction
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 2

An autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
164.1 TPM
Baço
67.3 TPM
Músculo esquelético
44.4 TPM
Pulmão
30.5 TPM
Cólon sigmoide
23.4 TPM
OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Bdistal myopathy with anterior tibial onsetMiyoshi muscular dystrophy 1autosomal recessive limb-girdle muscular dystrophy
HGNC:3097UniProt:O75923
ANO5Anoctamin-5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in plasma membrane repair in a process involving annexins (PubMed:33496727). Does not exhibit calcium-activated chloride channel (CaCC) activity

LOCALIZAÇÃO

Endoplasmic reticulum membraneCell membrane

VIAS BIOLÓGICAS (2)
Induction of Cell-Cell FusionStimuli-sensing channels
MECANISMO DE DOENÇA

Gnathodiaphyseal dysplasia

Rare skeletal syndrome characterized by bone fragility, sclerosis of tubular bones, and cemento-osseous lesions of the jawbone. Patients experience frequent bone fractures caused by trivial accidents in childhood; however the fractures heal normally without bone deformity. The jaw lesions replace the tooth-bearing segments of the maxilla and mandible with fibrous connective tissues, including various amounts of cementum-like calcified mass, sometimes causing facial deformities. Patients also have a propensity for jaw infection and often suffer from purulent osteomyelitis-like symptoms, such as swelling of and pus discharge from the gums, mobility of the teeth, insufficient healing after tooth extraction and exposure of the lesions into the oral cavity.

OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Lgnathodiaphyseal dysplasiaautosomal recessive limb-girdle muscular dystrophyMiyoshi muscular dystrophy 3
HGNC:27337UniProt:Q75V66
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cel

LOCALIZAÇÃO

Secreted, extracellular spaceSecreted, extracellular space, extracellular matrix, basement membraneSynapseCell membraneCytoplasm, cytoskeletonNucleus, nucleoplasmCell membrane, sarcolemmaPostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
DMPKMyotonin-protein kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus outer membraneMitochondrion outer membraneSarcoplasmic reticulum membraneCell membraneCytoplasm, cytosolMitochondrion membrane

VIAS BIOLÓGICAS (1)
Ion homeostasis
MECANISMO DE DOENÇA

Dystrophia myotonica 1

A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Junção
258.6 TPM
Esôfago - Muscular
241.8 TPM
Artéria tibial
229.7 TPM
Aorta
207.1 TPM
Cólon sigmoide
195.1 TPM
OUTRAS DOENÇAS (6)
myotonic dystrophy type 1adult-onset Steinert myotonic dystrophylate-onset Steinert myotonic dystrophycongenital-onset Steinert myotonic dystrophy
HGNC:2933UniProt:Q09013

Medicamentos e terapias

MEXILETINEPhase 3

Mecanismo: Sodium channel alpha subunit blocker

DEFLAZACORTPhase 3

Mecanismo: Glucocorticoid receptor agonist

TIDEGLUSIBPhase 2

Mecanismo: Glycogen synthase kinase-3 beta inhibitor

STAMULUMABPhase 1

Mecanismo: Growth/differentiation factor 8 inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

555 variantes patogênicas registradas no ClinVar.

🧬 CRPPA: NM_001101426.4(CRPPA):c.790-1G>A ()
🧬 CRPPA: NM_001101426.4(CRPPA):c.1097dup (p.Leu366fs) ()
🧬 CRPPA: NM_001101426.4(CRPPA):c.1171del (p.Asn390_Leu391insTer) ()
🧬 CRPPA: NM_001101426.4(CRPPA):c.1120-1G>A ()
🧬 CRPPA: GRCh37/hg19 7p22.3-14.3(chr7:158725-29918785)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 13 variantes classificadas pelo ClinVar.

10
3
Patogênica (76.9%)
VUS (23.1%)
VARIANTES MAIS SIGNIFICATIVAS
DMD: NM_004006.3(DMD):c.9072G>A (p.Trp3024Ter) [Pathogenic]
DMD: NM_004006.3(DMD):c.7327dup (p.Thr2443fs) [Pathogenic]
DMD: NM_004006.3(DMD):c.6291-1G>T [Likely pathogenic]
DMD: NM_004006.3(DMD):c.5611A>T (p.Lys1871Ter) [Pathogenic]
DMD: NM_004006.3(DMD):c.5612dup (p.Ala1872fs) [Pathogenic]

Vias biológicas (Reactome)

122 vias biológicas associadas aos genes desta condição.

Matriglycan biosynthesis on DAG1 Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 DAG1 core M2 glycosylations DAG1 core M3 glycosylations DAG1 core M1 glycosylations Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Constitutive Signaling by NOTCH1 HD Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus NOTCH3 Activation and Transmission of Signal to the Nucleus Formation of the dystrophin-glycoprotein complex (DGC) Retinoid metabolism and transport Meiotic synapsis Regulation of innate immune responses to cytosolic DNA Antigen processing: Ubiquitination & Proteasome degradation Assembly of collagen fibrils and other multimeric structures Caspase-mediated cleavage of cytoskeletal proteins Type I hemidesmosome assembly Striated Muscle Contraction COPI-dependent Golgi-to-ER retrograde traffic Kinesins Translocation of SLC2A4 (GLUT4) to the plasma membrane Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane Gap junction assembly MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Recruitment of NuMA to mitotic centrosomes Prefoldin mediated transfer of substrate to CCT/TriC Formation of tubulin folding intermediates by CCT/TriC Post-chaperonin tubulin folding pathway Recycling pathway of L1 Hedgehog 'off' state Cargo trafficking to the periciliary membrane Intraflagellar transport RHO GTPases activate IQGAPs RHO GTPases Activate Formins COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint Carboxyterminal post-translational modifications of tubulin HCMV Early Events Assembly and cell surface presentation of NMDA receptors Activation of AMPK downstream of NMDARs Aggrephagy EML4 and NUDC in mitotic spindle formation Sealing of the nuclear envelope (NE) by ESCRT-III RHOD GTPase cycle RHOF GTPase cycle PPARA activates gene expression Activation of gene expression by SREBF (SREBP) EGR2 and SOX10-mediated initiation of Schwann cell myelination Lanosterol biosynthesis Complement cascade Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation Pre-NOTCH Processing in the Endoplasmic Reticulum mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA mRNA Polyadenylation Dengue Virus-Host Interactions Inhibition of Host mRNA Processing and RNA Silencing mRNA 3'-end processing RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs Z-decay: degradation of maternal mRNAs by zygotically expressed factors Nuclear RNA decay Synthesis of GDP-mannose Expression of NOTCH2NL genes Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina XBP1(S) activates chaperone genes Depolymerization of the Nuclear Lamina Signaling by BRAF and RAF1 fusions Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models snRNP Assembly RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle RAC3 GTPase cycle Insertion of tail-anchored proteins into the endoplasmic reticulum membrane FGFR1b ligand binding and activation FGFR1c ligand binding and activation TGFBR3 regulates TGF-beta signaling TGFBR3 regulates FGF2 signaling RAB GEFs exchange GTP for GDP on RABs Laminin interactions Non-integrin membrane-ECM interactions ECM proteoglycans MET activates PTK2 signaling Attachment of bacteria to epithelial cells Developmental Lineage of Pancreatic Ductal Cells Platelet degranulation SARS-CoV-2 activates/modulates innate and adaptive immune responses Collagen degradation Collagen biosynthesis and modifying enzymes Collagen chain trimerization ABC transporters in lipid homeostasis RHOA GTPase cycle RHOC GTPase cycle Class I peroxisomal membrane protein import Signaling by PDGF Integrin cell surface interactions NCAM1 interactions PRC2 methylates histones and DNA NoRC negatively regulates rRNA expression SUMOylation of DNA methylation proteins DNA methylation Defective pyroptosis Degradation of the extracellular matrix Smooth Muscle Contraction Stimuli-sensing channels Induction of Cell-Cell Fusion Regulation of expression of SLITs and ROBOs Ion homeostasis

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 25
1Fase 13
·Pré-clínico14
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia muscular progressiva

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

19 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07543016 · Amino Acids and Exercise in FSHDRecrutando
NA
NCT07467187 · Invasive Home Ventilation in DenmarkRecrutando
NCT06817382 · A Study to Investigate the Safety and Biodistribution of a S…Recrutando
PHASE1
NCT07287189 · Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsRecrutando
PHASE2
NCT07127978 · A Study Evaluating the Real-World Experience of Givinostat i…Recrutando
NCT00004568 · Study of Inherited Neurological DisordersRecrutando
NCT07521930 · Interfacing With NeuroTechnology to Expand Neural Throughput…Recrutando
NA
NCT06839469 · Establishing Walking-related Digital Biomarkers in Rare Chil…Recrutando
NCT06503367 · Observation Study in Patients Age 0-5 Years With LAMA2-relat…Recrutando
NCT06280209 · A Phase 1/2 Study to Assess the Safety, Tolerability, Pharma…Recrutando
PHASE1, PHASE2
NCT07332013 · Urinary Titin Biomarker in DMDRecrutando
NA
NCT07515235 · DMD Gene Variants and Cardiac Dysfunction in Young Males Wit…Recrutando
NCT04626674 · A Gene Transfer Therapy Study to Evaluate the Safety of and …Recrutando
PHASE1
NCT06907875 · A First-in-human Study of EPI-321 in Facioscapulohumeral Mus…Recrutando
PHASE1, PHASE2
NCT00272883 · Molecular and Genetic Studies of Congenital MyopathiesRecrutando
NCT07478172 · Effects of Whole-body Electrical Muscle Stimulation Exercise…Recrutando
NA
NCT05237973 · Investigational Use of Neuromuscular UltrasoundRecrutando
NCT06491927 · Long Term Follow-up for RGX-202Por convite
NCT06066580 · Open-Label Extension of EDG-5506 in Participants With Becker…Por convite
PHASE2

Outros ensaios clínicos

856 ensaios clínicos encontrados, 30 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
74 papers (10 anos)
#1

Muscle meets Lysosomes: emerging strategies in muscular dystrophy.

Autophagy2026 Apr

Duchenne muscular dystrophy (DMD) is caused by the loss of DMD (dystrophin), leading to sarcolemmal fragility and progressive muscle degeneration. Although adeno-associated viral (AAV) microdystrophin (µDMD) therapies have advanced clinically, their benefits remain partial, highlighting the need to identify secondary cellular defects that limit therapeutic efficacy. In our recent study, we demonstrated that lysosomal dysfunction is a conserved, intrinsic, and persistent feature of DMD pathology. Using mouse, canine, and human dystrophic muscle, we show marked lysosomal membrane permeabilization (LMP), impaired acidification, defective proteolysis, and inefficient membrane repair, all hallmarks of compromised lysosomal integrity. Cholesterol accumulation within dystrophic myofibers further exacerbates these defects, linking lipid dysregulation to lysosomal injury and accelerated muscle degeneration. We find macroautophagy/autophagy impairment in DMD stems in part from reduced autophagosome-lysosome fusion, reframing autophagy failure as a downstream consequence of lysosomal damage. µDMD gene therapy only partially corrects these abnormalities and does not fully restore lysosomal stability. In contrast, combining µDMD with the lysosome-activating disaccharide trehalose produces synergistic benefits, improving muscle strength, architecture, and molecular signatures beyond either treatment alone. These findings position lysosomal dysfunction as a central driver of DMD pathophysiology and support therapeutic strategies that pair gene restoration with lysosomal enhancement.Abbreviation: AAV: adeno-associated virus; DAGC: DMD-associated glycoprotein complex; DMD: Duchenne muscular dystrophy; FDA: Food and Drug Administration; LMP: lysosome membrane permeabilization; MTOR: mechanistic target of rapamycin kinase; µDMD: microdystrophin.

#2

A national biobank framework for rare diseases: Standardized infrastructure and cross-institutional collaboration accelerating translational innovation in China.

HGG advances2026 Jan 15

Rare diseases (RDs) collectively affect >400 million people worldwide, but fragmented infrastructure and biospecimen scarcity impede progress. China's heterogeneous healthcare landscape magnifies these challenges. Since 2016, Peking Union Medical College Hospital (PUMCH) RD Biobank has pioneered a scalable model integrating 446 institutions via national networks, and setup Quality Management System since 2019 with the ISO 20387:2018, that received accreditation in 2022. Our secure digital platform standardizes biospecimen protocols (acquisition/processing/storage) and enables ethical data/specimen sharing through auditable Material Transfer Agreements/Data Use Agreements. Among 49,759 enrolled patients, 73.13% were diagnosed, while 26.87% were undiagnosed, with pediatric cases (50.75%) and males (52.39%) predominating. Phenotypic analysis showed 78.51% single-system versus 21.20% multisystem involvement. Top diagnoses included congenital scoliosis and progressive muscular dystrophy. Specimen diversity revealed system-specific patterns: musculoskeletal/nervous/sensory systems linked to multiple specimen types; immune/genitourinary to fluids; cardiovascular/neoplastic to derivatives; endocrine uniquely to tissues. Nucleic acids (93.4%) and blood specimens (21.4%) formed core resources, while induced pluripotent stem cells/organoids prioritized for cardiovascular/neoplastic RDs enable functional validation. This framework transcends biospecimen fragmentation by uniting clinical, molecular, and institutional dimensions. It demonstrates how centralized governance and interoperable systems can accelerate RD research globally. By transforming isolated data into collaborative discovery engines, we provide a blueprint for converting RD challenges into precision diagnostics and therapies, which are urgently needed for the millions of individuals worldwide who remain undiagnosed. Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of joint contractures that begin in early childhood; slowly progressive muscle weakness and wasting initially in a humeroperoneal distribution that later extends to the scapular and pelvic girdle muscles; and cardiac involvement that may manifest as palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure along with variable cardiac rhythm disturbances. Age of onset, severity, and progression of muscle and cardiac involvement demonstrate both inter- and intrafamilial variability. Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade, and respiratory function may be impaired in some individuals. The clinical diagnosis of EDMD can be established in a proband with characteristic early and prominent joint contractures, humeroperoneal (or more rarely limb-girdle) muscle weakness and wasting, and later-onset cardiac disease. The molecular diagnosis is established in a proband with characteristic clinical findings and a hemizygous pathogenic variant in EMD or FHL1, a heterozygous pathogenic variant in LMNA, SUN2, SYNE1, SYNE2, or TMEM43, or (more rarely) biallelic pathogenic variants in LMNA or SUN1 identified by molecular genetic testing. Treatment of manifestations: Surgery to release contractures and manage scoliosis as needed; aids (canes, walkers, orthoses, wheelchairs) as needed to help ambulation; physical therapy and stretching to prevent contractures. Treatment for cardiac disease can include antiarrhythmic drugs, oral anticoagulation, ablation procedures, cardiac pacemaker, implantable cardioverter-defibrillator, pharmacologic and nonpharmacologic therapy for heart failure; heart transplantation for the end stages of heart failure as appropriate; respiratory aids (respiratory muscle training, assisted coughing techniques, mechanical ventilation) as needed; in those with associated metabolic features, treatment may include dietary modification, medications to improve hypertriglyceridemia and hypercholesterolemia, and diabetes / insulin resistance medications. Surveillance: Assess joints for contractures and mobility, and spine for rigidity, posture, flexibility, swallowing function, and muscle strength at each visit; EKG, Holter monitor, and echocardiography at least annually; additional cardiac surveillance as needed; pulmonary function tests every two to three years and annually in those with respiratory compromise; cholesterol panel with triglycerides, hemoglobin A1c, and blood glucose every two to three years or more frequently in those with abnormalities. Agents/circumstances to avoid: Triggering agents for malignant hyperthermia, such as depolarizing muscle relaxants (succinylcholine) and volatile anesthetic drugs (halothane, isoflurane); obesity. Evaluation of relatives at risk: Molecular genetic testing if the pathogenic variant(s) in the family are known; clinical evaluation, including musculoskeletal evaluation and cardiac assessment, if the pathogenic variant(s) in the family are not known. EDMD is inherited in an X-linked (XL), autosomal dominant (AD), or (rarely) autosomal recessive (AR) manner. XL-EDMD: If the mother of a proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygous. Heterozygous females are usually asymptomatic but are at risk of developing cardiac disease, progressive muscular dystrophy (rare), and/or an EDMD phenotype (exceedingly rare). AD-EDMD: Sixty-five percent of individuals with LMNA-related AD-EDMD have a de novo pathogenic variant. Each child of an individual with AD-EDMD has a 50% chance of inheriting the pathogenic variant. AR-EDMD: If both parents are known to be heterozygous for a pathogenic variant associated with AR-EDMD, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants. Once the EDMD-related pathogenic variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing for EDMD are possible.

#3

AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.

Molecular therapy. Methods & clinical development2025 Sep 11

The aberrant expression of the toxic transcription factor DUX4 in skeletal muscle is a hallmark of facioscapulohumeral muscular dystrophy. Effective therapeutic strategies will likely require the inhibition of DUX4, with adeno-associated virus (AAV)-mediated therapies being among the promising approaches. However, the regenerative nature of muscle tissue can impact the long-term efficacy of AAV transduction, leading to reduced transgene persistence and diminishing the sustainability of gene inhibition over time. In this study, we utilized an AAV vector carrying a short hairpin RNA targeting DUX4 (shDUX4) to suppress DUX4 expression in the ACTA1-MCM; FLExDUX4/+ mouse model, which exhibits progressive muscular dystrophy. One month following AAV administration, the treatment significantly mitigated the DUX4-associated pathological features, including molecular, histopathological, and functional force-velocity-endurance (FoVE) parameters. However, by 10 months post-treatment, the therapeutic effects had substantially diminished, with most pathological markers remaining uncorrected and no sustained improvement in muscle force. This decline in therapeutic effect was associated with reduced DUX4 knockdown and a concurrent loss of AAV genomes. These findings highlight that although AAV-mediated gene therapy holds significant promise for FSHD treatment, challenges such as muscle fiber turnover and AAV genome dilution must be overcome to achieve sustained therapeutic benefit.

#4

Incidence and health burden of 20 rare neurological diseases in South China from 2016 to 2022: a hospital-based observational study.

Orphanet journal of rare diseases2025 Apr 08

Rare neurological diseases (RNDs) result in severe health burdens worldwide. Data from China are limited. We aimed to investigate the health burden of 20 RNDs in Guangdong Province (GD), which contains two-thirds of the population of South China. The hospitalization data of 20 RNDs were described using hospital-based front sheet data from 3,037 hospitals of GD from 2016 to 2022. The 20 RNDs included amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth Disease, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, congenital myotonia, congenital myasthenic syndrome, Dravet syndrome, Fabry disease, hereditary spastic paraplegia, Huntington disease, Leber hereditary optic neuropathy, mitochondrial encephalopathy (ME), multi-focal motor neuropathy, myotonic dystrophy, primary hereditary dystonia, progressive muscular dystrophy (PMD), spinal and bulbar muscular atrophy, spinal muscular atrophy (SMA), spinocerebellar ataxia, Wilson disease (WD) and X-linked adrenoleukodystrophy. Age were presented as mean and standard deviation while length of hospital stay as median and interquartile range (25th and 75th percentiles). The other variables were described as number and percentage. The data were analyzed by Joinpoint regression. There were 9,351 cases, including 330 ICU and 155 death cases. The average age was 33.7 ± 22.0 y, and 63.8% of patients were male. From 2016 to 2022, the number of RND (and juvenile RND) cases were 1034 (184), 1174 (293), 1443 (374), 1422 (320), 1331 (337), 1432 (409) to 1515 (515). ICU (and juvenile ICU) cases rose from 28 (3), 34 (6), 24 (4), 38 (11), 46 (13), 54 (24) to 106 (56). Joinpoint regression showed significant upward trend in percentages of juvenile and juvenile ICU cases (APC = 8.13, P< 0.05; APC = 28.42, P< 0.05). The fop five RNDs were WD, ASL, PMD, ME, and SMA, which accounted for 79.7% of all, 99.1% of ICU, and 94.8% of death cases. We demonstrated that the increase in health burden of RNDs was mainly evident in juveniles in South China from 2016 to 2022. The top 5 RNDs accounted for majority of the critical patients.

#5

Novel variant of COL12A1 gene causing neonatal hypotonia and respiratory failure.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025 Jun

The COL12A1 gene encodes Collagen XII α 1 chain, forming a biologically functional Collagen XII through a trimeric structure. Collagen XII dysfunction can lead to hereditary neuromuscular diseases with phenotypic profiles ranging from rare Ullrich congenital muscular dystrophy 2 (biallelic variant) to Bethlem myopathy 2 (uniallelic variant). Currently, only 29 COL12A1 deficiency cases have been reported, mainly featuring hypotonia, progressive muscular dystrophy, and skeletal deformities. Newborns cases were relatively rare. Here, we describe a neonate with hypotonia, weak spontaneous movement, convulsions, and respiratory failure at birth. Identification of a novel variant of COL12A1 by whole exome sequencing and Sanger sequencing, NM_004370.6: c.7622 C > T, p.Ser2541Phe. Molecular dynamics simulation revealed its location in the thrombospondin N-terminal domain, potentially destabilizing the Collagen XII trimer's structure. Our case report expands the COL12A1 genotype and phenotype spectrum, suggesting the presence of neonatal hypotonia and highlighting the importance of vigilance for respiratory clinical manifestations.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.104 artigos no totalmostrando 72

2026

Muscle meets Lysosomes: emerging strategies in muscular dystrophy.

Autophagy
2026

A national biobank framework for rare diseases: Standardized infrastructure and cross-institutional collaboration accelerating translational innovation in China.

HGG advances
2025

Clinical application of nanopore sequencing for haplotype linkage analysis in preimplantation genetic testing for Duchenne muscular dystrophy.

Scientific reports
2025

AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.

Molecular therapy. Methods &amp; clinical development
2025

Obligatory and accessory respiratory muscle structure, function and control in early and advanced disease in the mdx mouse model of Duchenne muscular dystrophy.

The Journal of physiology
2025

Incidence and health burden of 20 rare neurological diseases in South China from 2016 to 2022: a hospital-based observational study.

Orphanet journal of rare diseases
2025

Retinopathy associated with facioscapulohumeral muscular dystrophy. A case report treated with intravitreal dexamethasone implant and laser photocoagulation.

Archivos de la Sociedad Espanola de Oftalmologia
2025

Novel variant of COL12A1 gene causing neonatal hypotonia and respiratory failure.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2024

Asymptomatic and oligosymptomatic states of dysferlinopathy.

Journal of neuromuscular diseases
2025

Improving quality of life in palliative care: palatal lift prosthesis in a patient with periodontal disease.

BMJ case reports
2025

Characterization of Dystrophin Dp71 Expression and Interaction Partners in Embryonic Brain Development: Implications for Duchenne/Becker Muscular Dystrophy.

Molecular neurobiology
2024

Neurexin facilitates glycosylation of Dystroglycan to sustain muscle architecture and function in Drosophila.

Communications biology
2024

Molecular, Histological, and Functional Changes in Acta1-MCM;FLExDUX4/+ Mice.

International journal of molecular sciences
2024

Novel Variant in ANO5 Muscular Dystrophy: Identification by Whole Genome Sequencing and Quad Analysis.

Genes
2024

Unveiling the Respiratory Muscle Strength in Duchenne Muscular Dystrophy: The Impact of Nutrition and Thoracic Deformities, Beyond Spirometry.

Children (Basel, Switzerland)
2025

Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.

Cold Spring Harbor perspectives in biology
2024

Subspecialty Health Care Utilization in Pediatric Patients With Muscular Dystrophy in the United States.

Neurology. Clinical practice
2024

Appraising the Physical Activity Levels of Saudis with Physical Disabilities: Effects of Disability Type, Mobility Assistive Devices, and Demographic Factors.

Healthcare (Basel, Switzerland)
2023

[Searching for non-canonical functions of aminoacyl-tRNA synthases based on mutations carried by Charcot-Marie-Tooth patients].

Postepy biochemii
2023

A DMD case caused by X chromosome rearrangement.

Yi chuan = Hereditas
2023

Artificial Intelligence for Evaluation of Retinal Vasculopathy in Facioscapulohumeral Dystrophy Using OCT Angiography: A Case Series.

Diagnostics (Basel, Switzerland)
2023

Dystrophin (DMD) Missense Variant in Cats with Becker-Type Muscular Dystrophy.

International journal of molecular sciences
2023

Prevalence Study of Duchene Muscular Dystrophy and its Genetic Sequence in Southern India.

Iranian journal of child neurology
2023

A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable?

Journal of clinical medicine
2023

Minimal expression of dysferlin prevents development of dysferlinopathy in dysferlin exon 40a knockout mice.

Acta neuropathologica communications
2023

Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25.

Molecular therapy : the journal of the American Society of Gene Therapy
2024

Surgical treatment for lumbar hyperlordosis associated with facioscapulohumeral muscular dystrophy: A case series.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
2022

Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy.

Nature communications
2022

Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.

Muscle &amp; nerve
2022

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report.

OncoTargets and therapy
2022

The good, the bad, and the utilitarian: attitudes towards genetic testing and implications for disability.

Current psychology (New Brunswick, N.J.)
2021

Efficacy and safety of glucocorticoids in the treatment of progressive muscular dystrophy in children: a systematic review and meta-analysis.

Translational pediatrics
2021

Microhomology-Mediated Nonhomologous End Joining Caused Rearrangement of EMD and FLNA in Emery-Dreifuss Muscular Dystrophy.

Frontiers in genetics
2025

Pulmonary dysfunction in children with Duchenne muscular dystrophy may occur earlier than we thought - analysis using novel methodology based on z-scores.

Archives of medical science : AMS
2021

The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD.

Biomedicines
2020

[Professor LIN Guo-hua's experience in treatment of progressive muscular dystrophy with acupuncture].

Zhongguo zhen jiu = Chinese acupuncture &amp; moxibustion
2021

Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy.

Human gene therapy
2020

A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy.

Disease models &amp; mechanisms
2020

Ovine congenital progressive muscular dystrophy (OCPMD) is a model of TNNT1 congenital myopathy.

Acta neuropathologica communications
2020

LAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models.

Frontiers in molecular neuroscience
2020

A novel SYNE2 mutation identified by whole exome sequencing in a Korean family with Emery-Dreifuss muscular dystrophy.

Clinica chimica acta; international journal of clinical chemistry
2019

Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report.

World journal of clinical cases
2019

A newly discovered case of progressive muscular dystrophy caused by exon deletion mutation of Duchenne muscular dystrophy gene 12-28.

Journal of biological regulators and homeostatic agents
2019

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.

BMC neurology
2019

Chart validation of an algorithm for identifying hereditary progressive muscular dystrophy in healthcare claims.

BMC medical research methodology
2019

[Morphological characteristics of paravertebral muscles in patients with scoliosis caused by primaryprogressive muscular dystrophies].

Arkhiv patologii
2019

Proteomic identification of elevated saliva kallikrein levels in the mdx-4cv mouse model of Duchenne muscular dystrophy.

Biochemistry and biophysics reports
2019

A novel pathogenic variant in TNPO3 in a Hungarian family with limb-girdle muscular dystrophy 1F.

European journal of medical genetics
2018

Steroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report.

Neuromuscular disorders : NMD
2018

Human Adipose-Derived CD146+ Stem Cells Increase Life Span of a Muscular Dystrophy Mouse Model More Efficiently than Mesenchymal Stromal Cells.

DNA and cell biology
2018

A novel mutation in the DYSF gene in a patient with a presumed inflammatory myopathy.

Neuropathology : official journal of the Japanese Society of Neuropathology
2018

Effects of Ovariectomy in an hSOD1-G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS).

Medical science monitor : international medical journal of experimental and clinical research
2017

[Clinical and genetic characteristics of facioscapulohumeral muscular dystrophy Landuzi-Dezherina type 1].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2017

Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.

Skeletal muscle
2017

A De novo Mutation in Dystrophin Causing Muscular Dystrophy in a Female Patient.

Chinese medical journal
2017

Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma Developed in a Patient with Progressive Muscular Dystrophy: A Case Report and Review of the Literature.

Case reports in orthopedics
2017

A Japanese male with a novel ANO5 mutation with minimal muscle weakness and muscle pain till his late fifties.

Neuromuscular disorders : NMD
2017

Childhood Activity on Progression in Limb Girdle Muscular Dystrophy 2I.

Journal of child neurology
2017

γ-sarcoglycan and dystrophin mutation spectrum in an Algerian cohort.

Muscle &amp; nerve
2016

DNAJB6 Myopathies: Focused Review on an Emerging and Expanding Group of Myopathies.

Frontiers in molecular biosciences
2016

Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?

PloS one
2016

Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C).

Case reports in genetics
2016

A Case Report of an Infant with Robertsonian Translocation (15;22)(q10;q10) and Literature Review.

Annals of clinical and laboratory science
2016

Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage.

Histochemistry and cell biology
2015

[Diagnosis and natural history of Duchenne muscular dystrophy].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2015

Genetic characterization and improved genotyping of the dysferlin-deficient mouse strain Dysf (tm1Kcam).

Skeletal muscle
2015

Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A.

Skeletal muscle
2015

Pregnancy and delivery in Leyden-Möbius muscular dystrophy. Case Report.

Neuro endocrinology letters
2015

[Glucocorticoid therapy of progressive muscular dystrophy: the current state and progress].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2015

Motor unit reorganization in progressive muscular dystrophies and congenital myopathies.

Neurologia i neurochirurgia polska
2015

Plectin isoform P1b and P1d deficiencies differentially affect mitochondrial morphology and function in skeletal muscle.

Human molecular genetics
2015

Whole Exome Sequencing Reveals DYSF, FKTN, and ISPD Mutations in Congenital Muscular Dystrophy Without Brain or Eye Involvement.

Journal of neuromuscular diseases
Ver todos os 1.104 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia muscular progressiva.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia muscular progressiva

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Muscle meets Lysosomes: emerging strategies in muscular dystrophy.
    Autophagy· 2026· PMID 41532585mais citado
  2. A national biobank framework for rare diseases: Standardized infrastructure and cross-institutional collaboration accelerating translational innovation in China.
    HGG advances· 2026· PMID 41220173mais citado
  3. AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.
    Molecular therapy. Methods &amp; clinical development· 2025· PMID 40799204mais citado
  4. Incidence and health burden of 20 rare neurological diseases in South China from 2016 to 2022: a hospital-based observational study.
    Orphanet journal of rare diseases· 2025· PMID 40200352mais citado
  5. Novel variant of COL12A1 gene causing neonatal hypotonia and respiratory failure.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology· 2025· PMID 39985652mais citado
  6. Gmppb-mutant mice exhibit dystroglycanopathy symptoms that are rescued with GSK3β inhibition or AAV-mediated GMPPB gene replacement.
    Nat Commun· 2026· PMID 41957353recente
  7. Emery-Dreifuss Muscular Dystrophy.
    · 1993· PMID 20301609recente
  8. Clinical application of nanopore sequencing for haplotype linkage analysis in preimplantation genetic testing for Duchenne muscular dystrophy.
    Sci Rep· 2025· PMID 40835686recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:206644(Orphanet)
  2. MONDO:0016106(MONDO)
  3. GARD:20360(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55785935(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia muscular progressiva
Compêndio · Raras BR

Distrofia muscular progressiva

ORPHA:206644 · MONDO:0016106
Ensaios
30 ativos
Medicamentos
4 registrados
MedGen
UMLS
C4551827
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades